Biao Lu

685 total citations
27 papers, 505 citations indexed

About

Biao Lu is a scholar working on Oncology, Molecular Biology and Physiology. According to data from OpenAlex, Biao Lu has authored 27 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Physiology. Recurrent topics in Biao Lu's work include Pain Mechanisms and Treatments (5 papers), Migraine and Headache Studies (5 papers) and Botulinum Toxin and Related Neurological Disorders (4 papers). Biao Lu is often cited by papers focused on Pain Mechanisms and Treatments (5 papers), Migraine and Headache Studies (5 papers) and Botulinum Toxin and Related Neurological Disorders (4 papers). Biao Lu collaborates with scholars based in United States, China and Canada. Biao Lu's co-authors include Steven R. Deitcher, Katarína Petráková, George E. Peoples, Elizabeth A. Mittendorf, Adrian Murray Brunt, Igor Bondarenko, Michelle Melisko, Julie Price Hiller, Maria Alma Rodriguez and Robert Pytlík and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Biao Lu

25 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Biao Lu United States 10 204 182 116 86 72 27 505
Geng Xu China 14 183 0.9× 147 0.8× 62 0.5× 20 0.2× 64 0.9× 50 585
Andrew T. Lucas United States 13 218 1.1× 146 0.8× 49 0.4× 119 1.4× 28 0.4× 30 523
Arijit Bhowmik India 11 381 1.9× 147 0.8× 41 0.4× 103 1.2× 22 0.3× 27 686
Irena Maric Italy 12 171 0.8× 161 0.9× 140 1.2× 86 1.0× 23 0.3× 21 493
Da Li China 12 253 1.2× 282 1.5× 135 1.2× 45 0.5× 29 0.4× 33 728
Chia‐Yi Lin Taiwan 12 370 1.8× 55 0.3× 59 0.5× 40 0.5× 39 0.5× 25 611
Xifeng Dong China 13 209 1.0× 71 0.4× 47 0.4× 37 0.4× 50 0.7× 46 619
R Z Arzoomanian United States 10 326 1.6× 255 1.4× 62 0.5× 26 0.3× 46 0.6× 14 744
Yihang Qi China 13 217 1.1× 176 1.0× 84 0.7× 65 0.8× 41 0.6× 37 562
Elena‐Raluca Nicoli United States 17 273 1.3× 64 0.4× 48 0.4× 52 0.6× 152 2.1× 38 617

Countries citing papers authored by Biao Lu

Since Specialization
Citations

This map shows the geographic impact of Biao Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Biao Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Biao Lu more than expected).

Fields of papers citing papers by Biao Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Biao Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Biao Lu. The network helps show where Biao Lu may publish in the future.

Co-authorship network of co-authors of Biao Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Biao Lu. A scholar is included among the top collaborators of Biao Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Biao Lu. Biao Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tu, Peng, Yuanfeng Xia, Biao Lu, et al.. (2024). Design, Biological Characterization, and Discovery of Novel Cyclohexenyl Derivatives as Kinesin KIF18A Inhibitors for the Treatment of Ovarian Cancer. ACS Medicinal Chemistry Letters. 15(10). 1778–1786. 2 indexed citations
3.
Mittendorf, Elizabeth A., Biao Lu, Michelle Melisko, et al.. (2019). Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clinical Cancer Research. 25(14). 4248–4254. 153 indexed citations
4.
Reni, Michele, Jordan M. Winter, Giampaolo Tortora, et al.. (2019). Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. Annals of Oncology. 30. iv110–iv110. 3 indexed citations
5.
Lu, Biao, Xiaodong Shen, Lei Zhang, et al.. (2018). Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma. ACS Medicinal Chemistry Letters. 9(2). 98–102. 30 indexed citations
6.
Lu, Biao, Song Huang, Jingsong Cao, et al.. (2017). Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold. Bioorganic & Medicinal Chemistry. 26(3). 581–589. 17 indexed citations
7.
Nejadnik, Bijan, et al.. (2017). Treatment of essential thrombocytopenia patients intolerant/ resistant to hydroxyurea: A physician survey.. Journal of Clinical Oncology. 35(15_suppl). e18565–e18565.
8.
Zhang, Jiayin, Biao Lu, Dong Liu, et al.. (2016). EBI-907, a novel BRAFV600Einhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biology & Therapy. 17(2). 199–207. 11 indexed citations
9.
Raffa, Robert B., et al.. (2016). Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. Journal of Clinical Pharmacy and Therapeutics. 42(1). 8–17. 34 indexed citations
10.
Lu, Biao, Jingsong Cao, Song Huang, et al.. (2015). Discovery of EBI-907: A highly potent and orally active B-RafV600E inhibitor for the treatment of melanoma and associated cancers. Bioorganic & Medicinal Chemistry Letters. 26(3). 819–823. 8 indexed citations
11.
Kori, Shashidhar, et al.. (2013). Efficacy of MAP0004 in treating severe migraine. The Journal of Headache and Pain. 14(S1). 2 indexed citations
12.
Webster, Lynn R., John F. Peppin, Frederick T. Murphy, et al.. (2011). Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Research and Clinical Practice. 93(2). 187–197. 32 indexed citations
13.
14.
Lu, Biao, et al.. (2011). [Effects of multi-glycosides of tripterygium wilfordii on histological structures and c-kit expression in testes of pubertal rats].. PubMed. 13(10). 832–6. 1 indexed citations
15.
Malan, T. Philip, et al.. (2010). 505 DURATION OF TREATMENT RESPONSE TO QUTENZA (TM) (NGX‐4010), A HIGH‐CONCENTRATION CAPSAICIN PATCH, IN PATIENTS WITH POSTHERPETIC NEURALGIA. European Journal of Pain Supplements. 4(S1). 143–143. 2 indexed citations
16.
Rodriguez, Maria Alma, Robert Pytlík, Tomáš Kozák, et al.. (2009). Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma. Cancer. 115(15). 3475–3482. 105 indexed citations
17.
Thomas, Deborah A., Hagop M. Kantarjian, Wendy Stock, et al.. (2009). Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 115(23). 5490–5498. 34 indexed citations
18.
Bedikian, Agop Y., Nicholas E. Papadopoulos, Kevin B. Kim, et al.. (2008). A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Research. 18(6). 400–404. 25 indexed citations
19.
Thomas, Deborah A., Hagop M. Kantarjian, Wendy Stock, et al.. (2008). Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo™) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 112(11). 2930–2930. 4 indexed citations
20.
Batist, Gerald, John Sarantopoulos, Kamalesh K. Sankhala, et al.. (2007). A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease. Molecular Cancer Therapeutics. 6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Geng Xu Breakdown of academic impact, for papers by Andrew T. Lucas Breakdown of academic impact, for papers by Arijit Bhowmik Breakdown of academic impact, for papers by Irena Maric Breakdown of academic impact, for papers by Da Li Breakdown of academic impact, for papers by Chia‐Yi Lin Breakdown of academic impact, for papers by Xifeng Dong Breakdown of academic impact, for papers by R Z Arzoomanian Breakdown of academic impact, for papers by Yihang Qi Breakdown of academic impact, for papers by Elena‐Raluca Nicoli
Rankless by CCL
2026